WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > DONE Genetics and Bioinformatics Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
INDUSTRIAL IMPACT
c-LEcta | February 16, 2022
c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company. Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process development while also enabling c-...
MEDICAL
Mission Bio | March 15, 2022
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced new findings by Daniel Snellings from the lab of Douglas Marchuk, PhD, at Duke University School of Medicine using single-cell DNA sequencing to identify genetic mechanisms leading to the development of cerebral cavernous malformations (CCMs). The study, published today in the journal Nature Cardiovascular Research, is the latest demonstration of how Mission Bio's Tapestri Platform is allowing res...
PharmaMar | April 28, 2020
PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...
Bio-Techne | May 19, 2020
Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. Kantaro Biosciences is a joint venture between Mount Sinai Health System ("Mount Sinai") and Renalytix AI (LSE: RENX) formed exclusively to ensure that diagnostic tests for critical h...
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Whitepaper
MEDTECH
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE